This was the stock's third consecutive day of gains.
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday.
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") ...
The announcement comes directly from Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated, with the signatory on the report being Jonathan Biller, the Executive Vice President and Chief Legal Officer ...
Dec 20 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab next-generation treatment for a rare and progressive genetic disease ...